Ally Bridge Group NY LLC Sells 256,229 Shares of Geron Co. (NASDAQ:GERN)

Ally Bridge Group NY LLC cut its holdings in Geron Co. (NASDAQ:GERN - Free Report) by 19.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,074,824 shares of the biopharmaceutical company's stock after selling 256,229 shares during the period. Geron accounts for approximately 3.2% of Ally Bridge Group NY LLC's portfolio, making the stock its 13th biggest holding. Ally Bridge Group NY LLC owned 0.18% of Geron worth $3,805,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Rovin Capital UT ADV lifted its holdings in shares of Geron by 26.9% during the fourth quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company's stock worth $61,000 after buying an additional 3,660 shares during the last quarter. Xponance Inc. raised its holdings in Geron by 12.9% in the 4th quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company's stock valued at $150,000 after acquiring an additional 4,829 shares in the last quarter. KBC Group NV lifted its position in shares of Geron by 45.1% in the 4th quarter. KBC Group NV now owns 24,414 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 7,592 shares during the period. SBI Securities Co. Ltd. acquired a new stake in shares of Geron during the 4th quarter worth approximately $28,000. Finally, Lazari Capital Management Inc. increased its position in shares of Geron by 11.7% during the fourth quarter. Lazari Capital Management Inc. now owns 76,424 shares of the biopharmaceutical company's stock valued at $271,000 after purchasing an additional 8,000 shares during the period. Institutional investors and hedge funds own 73.71% of the company's stock.

Geron Price Performance

Shares of GERN traded down $0.05 during mid-day trading on Friday, hitting $1.38. 12,051,248 shares of the company traded hands, compared to its average volume of 11,373,087. Geron Co. has a one year low of $1.17 and a one year high of $5.34. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The business has a 50-day moving average of $1.53 and a 200 day moving average of $2.81. The stock has a market capitalization of $878.94 million, a price-to-earnings ratio of -4.31 and a beta of 0.66.

Geron (NASDAQ:GERN - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). The firm had revenue of $47.54 million for the quarter, compared to the consensus estimate of $45.29 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. As a group, equities analysts expect that Geron Co. will post -0.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on GERN shares. Barclays reiterated an "overweight" rating and set a $4.00 price target (down previously from $9.00) on shares of Geron in a research note on Thursday, February 27th. B. Riley cut shares of Geron from a "buy" rating to a "neutral" rating and lowered their target price for the company from $3.50 to $2.00 in a research note on Thursday, February 27th. Scotiabank cut their price target on shares of Geron from $6.00 to $4.00 and set a "sector outperform" rating for the company in a research note on Thursday, February 27th. Stifel Nicolaus lowered their price objective on Geron from $8.00 to $4.00 and set a "buy" rating on the stock in a research note on Thursday, February 27th. Finally, HC Wainwright restated a "neutral" rating on shares of Geron in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $5.38.

Geron Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.